SRDAN VERSTOVSEK to Clinical Trials, Phase II as Topic
This is a "connection" page, showing publications SRDAN VERSTOVSEK has written about Clinical Trials, Phase II as Topic.
Connection Strength
0.365
-
Genes Involved in Maintaining the Bone Marrow Stroma Are Dysregulated in Patients with Myelofibrosis: Lenalidomide Treatment Up-regulates SOCS3. Anticancer Res. 2015 Oct; 35(10):5219-23.
Score: 0.104
-
Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood. 2012 Aug 09; 120(6):1202-9.
Score: 0.083
-
Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial. Cancer. 2011 Nov 01; 117(21):4869-4877.
Score: 0.076
-
Imetelstat in intermediate-2 or high-risk myelofibrosis refractory to JAK inhibitor: IMpactMF phase III study design. Future Oncol. 2022 Jul; 18(22):2393-2402.
Score: 0.041
-
CD26 in T-cell lymphomas: a potential clinical role? Oncology (Williston Park). 2000 Jun; 14(6 Suppl 2):17-23.
Score: 0.036
-
Ruxolitinib for the treatment of patients with polycythemia vera. Expert Rev Hematol. 2015 Aug; 8(4):391-401.
Score: 0.025